Getinge AB Stock , GNGBF

	2023	2024	2025	2026
Revenue	-	31,605	33,251	37,494
Dividend	4.52	5.12	5.71	7.45
Dividend Yield (in %)	1.98 %	2.24 %	2.50 %	3.26 %
EPS	11.85	13.53	15.02	22.20
P/E Ratio	19.32	16.92	15.24	10.31
EBIT	4,474	5,105	5,670	7,998
EBITDA	-	7,069	7,732	9,845
Net Profit	3,029	3,497	3,922	5,827
Net Profit Adjusted	3,164	3,638	4,101	-
Pre-Tax Profit	4,262	4,910	5,501	7,868
Net Profit (Adjusted)	4,242	4,892	5,462	7,868
EPS (Non-GAAP) ex. SOE	-	-	-	-
EPS (GAAP)	11.01	12.79	14.37	21.29
Gross Income	14,836	15,870	17,053	19,634
Cash Flow from Investing	-1,216	-1,157	-1,199	-
Cash Flow from Operations	4,313	5,074	5,411	-
Cash Flow from Financing	-1,670	-1,579	-1,827	-
Cash Flow per Share	16.13	18.31	20.96	-
Free Cash Flow	3,010	3,720	4,168	-
Free Cash Flow per Share	17.83	19.09	20.69	-
Book Value per Share	117.14	125.10	134.53	-
Net Debt	166	-1,443	-3,460	-
Research & Development Exp.	1,193	1,217	1,264	1,241
Capital Expenditure	1,116	1,239	1,238	-
Selling, General & Admin. Exp.	8,775	9,137	9,603	-
Shareholder’s Equity	32,028	34,222	36,766	-
Total Assets	53,478	55,546	57,640	-

	Previous Quarter ending 12/31/22	Current Quarter ending 03/31/23	Next Quarter ending 06/30/23	Current Year ending 12/31/24	Next Year ending 12/31/25
Earnings Estimates
No. of Analysts	5	5	5	11	11
Average Estimate	3.516 SEK	1.839 SEK	2.535 SEK	11.848 SEK	13.527 SEK
Year Ago	4.540 SEK	2.110 SEK	2.330 SEK	10.900 SEK	11.848 SEK
Publish Date	2/1/2023	4/26/2023	7/18/2023	-	-
Revenue Estimates
No. of Analysts	6	5	5	11	11
Average Estimate	8,437 SEK	6,623 SEK	7,084 SEK	31,605 SEK	33,251 SEK
Year Ago	7,990 SEK	5,774 SEK	6,670 SEK	-	31,605 SEK
Publish Date	2/1/2023	4/26/2023	7/18/2023	-	-

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Getinge Dividend Calendar

Date	Name	Dividend	*yield	Currency
2022	Getinge AB	4.25	1.96	SEK
2021	Getinge AB	4.00	1.01	SEK
2020	Getinge AB	3.00	1.56	SEK
2019	Getinge AB	1.50	0.86	SEK
2018	Getinge AB	1.00	1.25	SEK
2017	Getinge AB	1.50	1.26	SEK
2016	Getinge AB	1.97	1.37	SEK
2015	Getinge AB	2.80	1.26	SEK
2015	Getinge AB	2.76	1.26	SEK
2014	Getinge AB	2.76	1.57	SEK
2014	Getinge AB	2.80	1.57	SEK
2013	Getinge AB	4.15	1.89	SEK
2013	Getinge AB	4.09	1.89	SEK
2012	Getinge AB	4.15	1.89	SEK
2012	Getinge AB	4.09	1.89	SEK
2011	Getinge AB	3.70	2.15	SEK
2011	Getinge AB	3.75	2.19	SEK
2010	Getinge AB	3.25	2.31	SEK
2010	Getinge AB	3.20	2.31	SEK
2009	Getinge AB	2.71	2.02	SEK
2009	Getinge AB	2.75	2.02	SEK

*Yield of the Respective Date

Getinge AB Calendar

Event	Estimate	Info	Date
Earnings Report	1.839 SEK	Q1 2023 Earnings Release	04/26/2023
Annual General Meeting	-	Annual General Meeting	04/26/2023
Earnings Report	2.535 SEK	Q2 2023 Earnings Release	07/18/2023
Earnings Report	-	Q3 2023 Earnings Release	10/23/2023
Earnings Report	-	Q4 2023 Earnings Release	01/25/2024
Earnings Report	-	Q1 2024 Earnings Release	04/23/2024
Earnings Report	-	Q2 2024 Earnings Release	07/16/2024
Earnings Report	-	Q3 2024 Earnings Release	10/18/2024

Getinge AB Past Events

Event	Actual EPS	Info	Date
Earnings Report	3.350 SEK	Q4 2022 Earnings Release	02/01/2023
Shareholders' Meeting	-	-	04/26/2022

Getinge Profile

Getinge AB is a medical technology company specializes in providing equipment, systems, operating rooms, intensive-care units to the healthcare and the life science industries. It offers products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. The firm operates through the following segments: Acute Care Therapies, Life Science and Surgical Workflows. The Acute Care Therapies segment offers solutions for life support in acute health conditions. The Life Science segment offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in biopharmaceutical production, biomedical research, medical device manufacturing and laboratory applications. The Surgical Workflows segment offers products and services for efficient disinfection and sterilization of instruments used in operations, operating tables and other high-quality hardware for operating rooms and advanced IT systems for efficient and secure hospital workflows. The company was founded by Olander Larsson in 1904 and is headquartered in Gothenburg, Sweden. .

Moody’s Daily Credit Risk Score

Risk

Low
Medium
High

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Getinge Shareholder

Owner	in %
Freefloat	85.53
Carl Reinhold Adolf Bennet, PhD, MBA	14.30
Fjärde AP-fonden	8.23
Fjarde AP Fonden	8.23
AMF Fonder AB	6.13
Swedbank Robur Fonder AB	3.85
Didner & Gerge Fonder AB	3.64
Incentive AS	2.77
Schroder Investment Management Ltd.	2.69
Norges Bank Investment Management	2.17
Government Pension Fund - Global (The)	2.15
Didner & Gerge Aktiefond	2.10
Carnegie Fonder AB	1.87
The Caisse de dépôt et placement du Québec	1.64
Bernstein Fund Inc. - International Strategic Equities Port.	1.34

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Getinge Management

Name	Job
Johan Malmquist	Chairman
Carsten Blecker	Chief Commercial Officer
Lars Sandström	Chief Financial Officer
Henrik Stenmo	Chief Financial Officer-Critical Care
Carl Reinhold Adolf Bennet	Deputy Chairman
Kristian Samuelsson	Director
Åke Larsson	Director
Dan Frohm	Director
Rickard Karlsson	Director
Fredrik Brattborn	Director
Magnus Lundbäck	Executive VP-Human Resources & Sustainability
Anna Romberg	Executive VP-Legal, Compliance & Governance
Joanna Engelke	Executive VP-Quality Compliance & Regulatory
Lars Mattsson	Head-Investor Relations
Cecilia Margaretha Daun-Wennborg	Independent Director
Eva Christina Malin Persson	Independent Director
Barbro Fridén	Independent Director
Johan Bygge	Independent Director
Mattias Sven Perjos	President, Chief Executive Officer & Director
Jens Viebke	President-Acute Care Therapies Business
Agneta Palmér	Vice President-Operational Services